New Dutch and Danish policies on allocating application time slots
This article was originally published in SRA
The Dutch Medicines Evaluation Board has announced a new policy for allocating time slots for marketing authorisation applications under the decentralised procedure where the Netherlands is acting as the reference member state1-3. The Danish Medicines Agency has followed suit. Both agencies say they need to schedule submissions in order to avoid overstretching their resources.